drugset / Trial / NCT03522688

Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

NCT03522688 ↗

Phase 4 Unknown 214 enrolled Asan Medical Center
RandomizedParallel-groupDouble-blindPrevention

Summary

Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Timeline

Start
2017-07-11
Primary completion
2023-07-14
Completion
2024-07-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.4 ug/kg Intravenous